HBM Holdings Sets Commercial Path for Core Myasthenia Drug in Greater China (TipRanks) - Sep 21, 2026 - "The company has provided an update that Batoclimab (HBM9161), its core product for generalized myasthenia gravis, has had its biologics license application accepted by China's NMPA and is expected, subject to regulatory review, to obtain marketing authorization in the second half of 2026."
China approval • China filing • Myasthenia Gravis
|